EPS-G7: Ethylene-based Blocking Technology Enhances Amylase Detection Specificity

In clinical biochemical testing, the accuracy of α-amylase activity measurement depends not only on instruments and procedures but also on the design quality of the substrate itself. As the recommended assay substrate by the International Federation of Clinical Chemistry, EPS-G7 features ethylidene blocking modification in its molecular structure, which fundamentally resolves the issue of nonspecific interference present in traditional methods, ensuring more reliable test results.

Ethylene closure: eliminating interference from a structural perspective

The core design of EPS-G7 substrate lies in the ethylene modification at its non-reducing end. In the EPS-G7 molecule, the non-reducing end of the maltose heptose chain is precisely blocked by ethylene. This modification blocks the direct hydrolysis of the intact substrate by α-glucosidase at the molecular level. Without this blocking modification, the auxiliary enzyme α-glucosidase would attack the non-reducing end of the substrate molecule before the action of α-amylase, gradually cleaving glucose units and releasing p-nitrophenol. This non-specific hydrolysis leads to elevated background signals in the reaction system, which are unrelated to the true activity of α-amylase in the sample and directly interfere with the accuracy of the detection results.

The introduction of ethylene closure modification ensures that the reaction can only be triggered by the target enzyme α-amylase. Only after α-amylase cleaves the glycosidic bond from within the polysaccharide chain does the auxiliary enzyme function, fully releasing the p-nitrophenyl group. This sequential mechanism of "blockage-cutting-release" eliminates nonspecific interference at the source, ensuring a direct correspondence between the detection signal and the activity of α-amylase.

Performance enhancement beyond the traditional PNP-G7 method

Compared to the PNP-G7 substrate used earlier, EPS-G7 has achieved significant improvements in detection specificity and accuracy. The PNP-G7 substrate lacks non-reducing end blocking modifications, allowing α-glucosidase to directly act on intact substrate molecules, resulting in higher background signals in the detection system. This background interference is particularly pronounced in samples with low enzyme activity, affecting the results more significantly. EPS-G7 addresses this issue through ethylene blocking modifications, enabling the detection signal to more accurately reflect the α-amylase activity in the sample. Additionally, the blocking modifications enhance the overall chemical stability of the substrate molecules, extending the shelf life of the reagent, reducing performance variations between different batches, and improving the consistency and reliability of clinical testing.

The clinical application value of multi matrix samples

EPS-G7 substrate is suitable for in vitro quantitative analysis of various matrix samples such as human serum, plasma, and urine. Strong sample compatibility and high detection sensitivity can quickly and accurately reflect the activity level of amylase in the body, providing quantitative data support for clinical decision-making. In terms of disease diagnosis, alpha amylase testing is the preferred indicator for clinical screening of acute pancreatitis. During the onset of acute pancreatitis, the rapid increase of serum amylase in a short period of time is an important warning signal. Meanwhile, EPS-G7 substrate also provides laboratory evidence for the diagnosis, dynamic monitoring, and efficacy evaluation of chronic pancreatitis, salivary gland suppuration or duct obstruction, as well as mumps and other diseases.

Reliable basis for clinical testing

The value of EPS-G7 substrate lies in its guarantee of detection specificity and adaptability to multiple sample types. Through the core technology of ethylene block modification, the results of alpha amylase detection can better reflect the true pathological and physiological state, reducing false results caused by non-specific interference. This makes EPS-G7 substrate an irreplaceable component in clinical biochemical detection systems and provides reliable technical support for the diagnosis of pancreatic and glandular related diseases. The EPS-G7 substrate produced by Xindesheng is strictly controlled according to quality standards and can meet the requirements of clinical testing for substrate performance.

Hubei Xindesheng Material Technology Company has completed the research and sales of EPS-G7 substrate, with mature and stable production technology and good product quality. If you have any related procurement needs in the near future, please click on the official website for more details or contact me directly!